Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3457–3466. doi: 10.1158/1055-9965.EPI-08-0517

Table 1.

Age-adjusted ORs and 95% CIs for CYP19A1 genotypes and risk of breast cancer and fibrocystic conditions, by proliferative status

Breast cancer Fibrocystic conditions


Controls All With non-proliferative
fibrocystic conditions
With proliferative
fibrocystic conditions
All Non-proliferative Proliferative


n n OR 95% CI n OR 95% CI n OR 95% CI n OR 95% CI n OR 95% CI n OR 95% CI
Block 1 SNPs
rs1870049
TT 548 371 1.00 (ref) 75 1.00 (ref) 67 1.00 (ref) 278 1.00 (ref) 99 1.00 (ref) 117 1.00 (ref)
CT 292 211 1.06 (0.85–1.33) 44 1.08 (0.73–1.62) 41 1.14 (0.75–1.72) 154 1.05 (0.82–1.35) 44 0.85 (0.58–1.25) 55 0.90 (0.63–1.29)
CC 38 30 1.18 (0.72–1.94) 5 1.02 (0.39–2.69) 8 1.78 (0.79–3.98) 32 1.48 (0.89–2.43) 11 1.38 (0.68–2.82) 10 1.12 (0.54–2.33)
rs1004982
TT 410 291 1.00 (ref) 61 1.00 (ref) 44 1.00 (ref) 208 1.00 (ref) 75 1.00 (ref) 81 1.00 (ref)
CT 371 245 0.92 (0.74–1.15) 51 0.90 (0.60–1.34) 48 1.18 (0.77–1.82) 193 1.05 (0.82–1.34) 58 0.89 (0.61–1.30) 79 1.11 (0.79–1.57)
CC 90 72 1.13 (0.80–1.60) 12 0.93 (0.48–1.80) 21 2.19 (1.24–3.85) 63 1.31 (0.91–1.90) 21 1.21 (0.70–2.08) 21 1.15 (0.67–1.97)
Block 2 SNPs
rs28566535
AA 404 278 1.00 (ref) 55 1.00 (ref) 45 1.00 (ref) 203 1.00 (ref) 73 1.00 (ref) 80 1.00 (ref)
AC 370 259 1.01 (0.81–1.26) 59 1.14 (0.77–1.70) 45 1.08 (0.70–1.67) 203 1.10 (0.86–1.41) 63 0.97 (0.67–1.40) 84 1.18 (0.84–1.66)
CC 94 71 1.09 (0.78–1.54) 11 0.87 (0.44–1.72) 23 2.20 (1.27–3.82) 55 1.10 (0.75–1.61) 18 1.01 (0.57–1.77) 17 0.89 (0.50–1.58)
rs936306
CC 405 279 1.00 (ref) 58 1.00 (ref) 49 1.00 (ref) 205 1.00 (ref) 75 1.00 (ref) 80 1.00 (ref)
CT 368 257 1.01 (0.81–1.26) 54 1.00 (0.67–1.48) 42 0.93 (0.60–1.44) 208 1.15 (0.90–1.47) 59 0.91 (0.62–1.32) 87 1.24 (0.88–1.74)
TT 102 77 1.09 (0.78–1.52) 13 0.88 (0.47–1.68) 24 1.94 (1.13–3.30) 52 0.99 (0.67–1.44) 20 1.04 (0.60–1.79) 15 0.74 (0.41–1.35)
Block 3 SNP
rs11636639
GG 244 173 1.00 (ref) 34 1.00 (ref) 31 1.00 (ref) 131 1.00 (ref) 44 1.00 (ref) 51 1.00 (ref)
GT 410 289 1.00 (0.78–1.28) 54 0.97 (0.61–1.53) 59 1.14 (0.71–1.80) 213 0.94 (0.72–1.24) 65 0.87 (0.57–1.32) 89 1.03 (0.70–1.50)
TT 198 140 1.01 (0.75–1.35) 32 1.24 (0.74–2.10) 25 1.02 (0.58–1.80) 110 0.97 (0.70–1.34) 40 1.07 (0.67–1.72) 38 0.87 (0.55–1.39)
Block 4 SNPs
rs767199
AA 185 126 1.00 (ref) 31 1.00 (ref) 17 1.00 (ref) 97 1.00 (ref) 36 1.00 (ref) 34 1.00 (ref)
AG 438 294 0.98 (0.75–1.28) 57 0.76 (0.47–1.21) 59 1.45 (0.82–2.55) 219 0.98 (0.72–1.32) 68 0.83 (0.53–1.29) 88 1.12 (0.72–1.73)
GG 255 191 1.10 (0.82–1.47) 37 0.86 (0.51–1.44) 38 1.61 (0.88–2.94) 149 1.13 (0.82–1.57) 50 1.02 (0.63–1.63) 60 1.32 (0.83–2.10)
rs4775936
TT 174 114 1.00 (ref) 27 1.00 (ref) 16 1.00 (ref) 100 1.00 (ref) 36 1.00 (ref) 38 1.00 (ref)
CT 459 302 1.00 (0.76–1.32) 52 0.71 (0.43–1.16) 55 1.28 (0.71–2.30) 221 0.86 (0.64–1.16) 65 0.71 (0.46–1.12) 89 0.92 (0.61–1.41)
CC 243 196 1.23 (0.91–1.66) 46 1.21 (0.72–2.02) 44 1.95 (1.07–3.58) 144 1.03 (0.74–1.43) 53 1.03 (0.64–1.66) 55 1.05 (0.66–1.66)
rs11575899
INS/INS 453 309 1.00 (ref) 66 1.00 (ref) 57 1.00 (ref) 247 1.00 (ref) 81 1.00 (ref) 92 1.00 (ref)
INS/DEL 358 252 1.03 (0.83–1.28) 52 1.01 (0.68–1.49) 45 1.01 (0.66–1.52) 174 0.87 (0.68–1.11) 57 0.87 (0.60–1.26) 71 0.96 (0.68–1.35)
DEL/DEL 65 50 1.14 (0.76–1.69) 7 0.76 (0.34–1.74) 12 1.50 (0.76–2.95) 42 1.12 (0.73–1.72) 15 1.21 (0.65–2.24) 18 1.25 (0.71–2.23)
rs10046
TT 277 178 1.00 (ref) 46 1.00 (ref) 30 1.00 (ref) 152 1.00 (ref) 55 1.00 (ref) 54 1.00 (ref)
CT 436 308 1.10 (0.86–1.39) 52 0.71 (0.47–1.09) 67 1.41 (0.89–2.22) 210 0.88 (0.67–1.14) 62 0.72 (0.48–1.07) 84 0.99 (0.68–1.45)
CC 163 125 1.19 (0.88–1.61) 27 1.01 (0.60–1.69) 17 0.97 (0.52–1.81) 99 1.08 (0.78–1.50) 34 0.99 (0.62–1.60) 43 1.34 (0.86–2.10)
rs4646
GG 441 298 1.00 (ref) 64 1.00 (ref) 56 1.00 (ref) 240 1.00 (ref) 81 1.00 (ref) 87 1.00 (ref)
GT 358 260 1.08 (0.87–1.34) 53 1.04 (0.70–1.53) 50 1.10 (0.73–1.65) 177 0.89 (0.70–1.14) 57 0.85 (0.59–1.24) 72 1.01 (0.71–1.42)
TT 77 53 1.03 (0.70–1.50) 8 0.75 (0.34–1.62) 8 0.83 (0.38–1.82) 45 1.03 (0.68–1.54) 14 0.92 (0.49–1.72) 22 1.36 (0.80–2.32)
HHS Vulnerability Disclosure